News Release

New research initiative launches for all patients ever diagnosed with colorectal cancer

The Colorectal Cancer Project allows patients to easily share their data with research community

Business Announcement

Dana-Farber Cancer Institute

Count Me In

image: Count Me In view more 

Credit: Count Me In

BOSTON – Count Me In, a nonprofit cancer research initiative, is inviting all patients across the United States and Canada who have ever been diagnosed with colorectal cancer to participate in research and help drive new discoveries related to this disease. The Colorectal Cancer Project which launches today will enable patients to easily share their samples, health information and personal lived experiences directly with researchers in order to accelerate the pace of research. The resulting de-identified data from patients participating in the project will help lead to better understanding of this disease and ultimately better therapies for colorectal cancer. 

Patients who have been diagnosed with colorectal cancer at any point in their lives can join the project by visiting From there, patients will be invited to share information about their experience through surveys and to provide access to medical records as well as saliva samples and optional blood, stool, and/or stored tissue samples for study and analysis. Researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute use this information to generate databases of clinical, genomic, molecular, and patient-reported data that is then de-identified and shared with researchers everywhere. Insights gleaned from the research will also be shared with patients participating in the project. To date, more than 9,000 patients with different cancers have joined Count Me In and shared their data.

The launch of the Colorectal Cancer Project comes at a time when a particularly concerning increase in colorectal cancer incidence among younger individuals has been observed. Since 1994, colorectal cancer has increased by 51 percent in individuals younger than 50, according to the National Cancer Institute. The rising incidence of young-onset colorectal cancer has recently led the American Cancer Society to revise its colorectal screening guidelines to start earlier at age 45 instead of 50. 

"Colorectal cancer is the second leading cause of cancer death in the U.S. and is on track to become the leading cause of cancer death in people aged 20-49 by 2030. These cancers are developing in otherwise young and healthy people who have no risk factors,” said Kimmie Ng, MD, MPH, the director of the Young-Onset Colorectal Cancer Center at Dana-Farber and co-scientific leader of the Colorectal Cancer Project. “Understanding why these rates are rising is what keeps me up at night and why we have redoubled our efforts to tackle this problem. The Colorectal Cancer Project will connect patients and researchers to accelerate the search for answers and solutions to this troubling trend." 

Colorectal cancer also disproportionately affects African Americans who are approximately 20% more likely to get colorectal cancer and about 40% more likely to die from the disease than most other racial groups according to the American Cancer Society. 

Inviting all colorectal cancer patients from any age, background, or stage to join the project adds tremendous scientific value to the data that is ultimately generated. The inclusion of a larger, more diverse patient population enables the study of patients who may have received a particular therapy for treatment of their disease,  patients who might share a specific rare mutation in their tumor, or those from a specific age group or background who are otherwise underrepresented in existing research studies. 

“We still do not know why there is an alarming rise in colorectal cancer in young adults”, said  Andrea Cercek, MD Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers Memorial Sloan Kettering Cancer Center and co-scientific leader of the Colorectal Cancer Project. “What we do know is that this is a global phenomenon that affects otherwise healthy individuals with no known risk factors. The Colorectal Cancer Project will provide researchers important information that will lead to a better understanding of this disease.”

Count Me In’s research model also seeks to empower all individuals living with cancer, including those from marginalized communities who have historically been excluded from research, no matter where they live, to contribute to groundbreaking cancer research. Due to the fact that the majority of cancer patients have not had the opportunity to participate in research — because most cancer patients are cared for in community settings where this type of research is not done — most patients have never been asked if they’d like to contribute their tissue samples and medical information for research.


About Count Me In


Count Me In is a research initiative that enables cancer patients to directly transform cancer research and discovery. Individuals in the United States or Canada who have ever been diagnosed with cancer can share information about their experience by completing surveys, sharing biological sample(s), and copies of their medical records with researchers in order to accelerate discoveries. De-identified clinical, genomic, and patient-reported data is shared with the scientific community with the aim of learning from every cancer patient’s experience, regardless of where they live.


About the Broad Institute of MIT and Harvard 

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community. 

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.